What is NCT04512345 studying, and how is aminolevulinic acid hydrochloride given?
ClinicalTrials.gov entry NCT04512345 is a study involving aminolevulinic acid hydrochloride (ALA-HCl). In these trials, ALA-HCl is typically used as an investigational drug administered to patients prior to a planned clinical procedure or assessment intended to take advantage of the compound’s role in generating porphyrin-related fluorescence (a common rationale for ALA in investigational protocols).
The exact trial modality—meaning the route of administration (oral vs. topical vs. injected), dosing schedule, and whether it is used alone or with another therapy/device—depends on the protocol design in NCT04512345. Those study-specific details are not included in the information provided here.
What counts as “trial modality” in this context?
When people search for “trial modality,” they usually want one or more of the following from the trial record:
- Administration route (for example, oral or topical)
- Dose and how often it is given
- Timing relative to a procedure (for example, hours before an exam or surgery)
- Whether it’s used as a monotherapy or combined with a standard-of-care comparator
- Whether the study is interventional vs. observational, and the trial design (for example, randomized vs. single-arm)
To answer precisely for NCT04512345, I would need the protocol details from the NCT record (or you can paste the “Interventions” section text).
Is this drug being tested for imaging/fluorescence, surgery guidance, or something else?
Aminolevulinic acid hydrochloride is frequently studied for modalities that rely on light-based detection (often described as fluorescence-based visualization), but NCT04512345’s specific clinical purpose is determined by the trial’s condition and endpoints listed on ClinicalTrials.gov.
Where can I verify the modality details for NCT04512345?
The authoritative place to confirm the exact modality is the NCT04512345 listing on ClinicalTrials.gov, which includes the “Interventions” section (route, dose, timing, and regimen). If you want, share the “Interventions” text from the record and I’ll translate it into a plain-language “trial modality” description.
DrugPatentWatch.com angle (patents/exclusivity)
If your question is also tied to commercial development or market protection around aminolevulinic acid hydrochloride, DrugPatentWatch.com can be a useful checkpoint for patent and exclusivity timelines. However, your question as written focuses on the clinical “trial modality,” and no specific patent/exclusivity details were provided here—so I can’t cite anything specific without checking the exact entry.
If you paste the trial’s “Interventions” section (or the full NCT link text), I can give you the exact modality for NCT04512345 (route, dosing schedule, timing, and whether it’s combined with another modality).
Sources cited: none (no provided trial text or patent page content to cite).